Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

  • December 2016 •
  • 363 pages •
  • Report ID: 4590213 •
  • Format: PDF
Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market
Summary
Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient’s immune system in a general way or aiding the identification of specific antigens associated with the cancer. The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells.

The market size for cancer immunotherapies is expected to grow at an exceptional rate over the forecast period, from $16.9 Billion in 2015 to $75.8 Billion in 2022, at a compound annual growth rate (CAGR) of 23.9%. The forecast for the most optimistic outcome has the market reach $82.1 Billion in 2022, at a CAGR of 25.3%. The US market is forecast to grow at a similarly rapid rate, from $9.5 Billion in 2015 to $40.8 Billion in 2022, which equates to just over half of the total market size throughout the forecast period.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to the growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

According to Yasser Mushtaq, “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans.”

The report “Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market” provides an introduction to key indications within cancer immunotherapies, including disease epidemiology, symptoms, pathophysiology, diagnosis and disease staging and prognosis.

In depth, it provides the following -
- Provides an overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
- Analyzes the cancer immunotherapies pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast cancer, melanoma, NSCLC and ovarian cancer.
- Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
- Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
- Analyzes trends in co-development and licensing deals, relating to cancer immunotherapy products.

Scope
The cancer immunotherapies market already consists of some commercially successful products.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?
The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.
- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?
The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.
- Which products are forecast to drive this substantial degree of growth?
- Will generic competition have a significant impact on the market over the forecast period?
The company landscape is growing increasingly competitive.
- What are the leading companies in terms of market share?
- Which companies are forecast to experience the greatest growth in market share?
- What are the drivers of growth for key companies in the market?
- How dependent are the key companies on this disease cluster for revenue?
- Which companies rely heavily on this disease cluster for revenue?

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which includes breast cancer, melanoma, NSCLC and ovarian cancer.
- Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from cancer immunotherapy products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.